

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants:** 

Elisabeth M. Bock, et al.

**Examiner:** 

Unassigned

Serial No.:

09/781,509

**Art Unit:** 

Unassigned

Filed:

February 12, 2001

Docket:

12754A

For: NEUROGENIC COMPOSITIONS

AND METHODS

Dated:

May 11, 2001

Assistant Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

- 1. International Patent No. WO 92/10200, published June 25, 1992;
- 2. International Patent No. WO 95/20656, published August 3, 1995;

## CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on May 11, 2001.

Dated: May 11, 2001

Lanet Grossman

- 3. Winningham-Major, F., et al. (1989) "Neurite Extension and Neuronal Survival Activities of Recombinant S100B Proteins That Differ in The Content and Position of Cysteine Residues", The Journal of Cell Biology, Vol. 109, pp. 3063-3071;
- 4. Azmitia, E.C., et al. (1990) "S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor", Elsevier Science Publishers B.V. (Biomedical Division);
- 5. Ebralidze, A., et al. (1989) "Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca<sup>2</sup>+-binding protein family", Genes and Development, US, Cold Spring Harbor, NY, Vol. 3, 1994, pp. 1086-1093; and
- 6. Klingman, D., et al. "The S100 Protein Family", Trends in Biochemical Sciences, Vol. 13, No. 11, 1988, pp. 437-443.

The references were cited in a Search Report received from the International Patent Office dated February 26, 2001. Applicants are submitting copies of the above-cited references, along with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

It is further noted that Reference No. 5, the article by Ebralidze, A., et al., was previously submitted in a prior Information Disclosure Statement dated February 12, 2001 in connection with the above-identified application.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,

Frank S. DiGiglio Registration No. 31,346

Scully, Scott, Murphy & Presser 400 Garden City Plaza Garden City, New York 11530 (516) 742-4343

FSD:ahs/tt

 د د بر	SIR		(.17)	D-100/		
RANSI MAY	MITTAL OF	F INFORMATION DISCLOSURE S' nder 37 CFR 1.97(b) or 1.97(c))	TATEMENT	Docket No. 12754A		
<u>a</u>		Elisabeth M. Bock, et al.				
09/	erial No. 7781,509	Filing Date February 12, 2001	Examiner Unassigned	Group Art Unit Unassigned		
Title: N	IEUROGENIC	COMPOSITIONS AND METHODS				
		Address to:  Assistant Commissioner  Washington, D.C.	for Patents 20231			
		37 CFR 1.97	(b)			
1 i	The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.					
		37 CFR 1.97				
	The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:					
	1.	a Final Action under 37 CFR 1.113, or				
I I	2.	a Notice of Allowance under 37 CFR 1.	.311,			
	which	hever occurs first.				
	Also submitte	ed herewith is:				
	a certi	ification as specified in 37 CFR 1.97(e);				
		OR				
	the fe	ee set forth in 37 CFR 1.17(p) for submise 37 CFR 1.97(c).	ission of an Informatior	n Disclosure Statement		
1						

### TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. 12754A (Under 37 CFR 1.97(b) or 1.97(c)) In Re Application Of: Elisabeth M. Bock, et al.

Serial No.

Filing Date

Examiner

Group Art Unit

09/781,509

February 12, 2001

Unassigned

Unassigned

Title: NEUROGENIC COMPOSITIONS AND METHODS

#### Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of

is attached.


The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of

Credit any overpayment. X

Charge any additional fee required.

Certificate of Transmission by Facsimile\*



\*This certificate may only be used if paying by deposit account.

Signature

Certificate of Mailing by First Class Mail

1 certify that this document and fee is being deposited on with the U.S. Postal Service as first May 11, 2001 class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Dated: May 11, 2001

Janet Grossman

Typed or Printed Name of Person Mailing Correspondence

Frank S. DiGiglio Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER 400 Garden City Plaza Garden City, New York 11530

(516) 742-4343

FSD:ahs/tt

CC:

Copyright 1996 Legalsoft

P10A/REV01

	SMITTAL OF	Docket No. 12754A					
		isabeth M. Bock, et al.					
TOWN				Group Art Unit			
Serial No. 09/781,509		Filing Date February 12, 2001	Examiner Unassigned	Unassigned			
Title:	NEUROGENIC (	COMPOSITIONS AND METHOD	S				
		Assistant Commi	ress to: issioner for Patents n, D.C. 20231				
		37 CF	R 1.97(b)				
1. 🗷	The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.						
			R 1.97(c)				
2. 🗇	of a national a	n Disclosure Statement submitted pplication, or the date of entry of pplication; or after the mailing dut before the mailing date of eithe	ate of a first Office Action or	nree months of the filing in in 37 CFR 1.491 in an in the merits, whichever			
	1.	a Final Action under 37 CFR 1.1	13, or				
ı	2.	a Notice of Allowance under 37	CFR 1.311,				
-	whichever occurs first.						
	Also submitted	herewith is:					
	☐ a certifi	cation as specified in 37 CFR 1.97	7(e);				
		OR					
	the fee	set forth in 37 CFR 1.17(p) for 37 CFR 1.97(c).	submission of an Information	Disclosure Statement			

### OF INFORMATION DISCLOSURE STATEMENT Docket No. 12754A (Under 37 CFR 1.97(b) or 1.97(c)) Elisabeth M. Bock, et al. e Application **DEMAP** Group Art Unit Examiner Filing Date Serial No. Unassigned Unassigned February 12, 2001 09/781,509 Title: NEUROGENIC COMPOSITIONS AND METHODS Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) is attached. A check in the amount of The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed. Charge the amount of Credit any overpayment. X Charge any additional fee required. X Certificate of Mailing by First Class Mail Certificate of Transmission by Facsimile\* I certify that this document and fee is being deposited on I certify that this document and authorization to charge deposit with the U.S. Postal Service as first May 11, 2001 account is being facsimile transmitted to the United States class mail under 37 C.F.R. 1.8 and is addressed to the Patent and Trademark Office (Fax. No. Assistant Commissioner for Patents, Washington, D.C. 20231. (Date) Signatur Janet Grossman Typed or Printed Name of Person Mailing Correspondence Typed or Printed Name of Person Signing Certificate \*This certificate may only be used if paying by deposit account. Dated: May 11, 2001 Frank S. DiGiglio Registration No. 31,346 SCULLY, SCOTT, MURPHY & PRESSER 400 Garden City Plaza Garden City, New York 11530 (516) 742-4343 FSD:ahs/tt CC:

Copyright 1996 Legalsoft

P1CA/REVC1